Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 24, 2017
Pharmacy Choice - News - Generic Drugs - April 24, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 64     Next >>     Go To Page:

4/24/17 - Canada Generic Drug Market Report 2017: Driven by Continuous Expiration of Drug Patents, Rising Aging Population & Increasing Prevalence of Chronic Diseases - Research and Markets
Research and Markets has announced the addition of the " Canada Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report to their offering. Canada represents the world's ninth biggest market for generic drugs in terms of value. Over the past few decades, the acceptance and use of generic drugs in Canada
4/24/17 - Generic Oncology Drug Market 2017-2022: Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts Featuring Freseunis, Hospira, Mylan, Novartis & Sandoz - Research and Markets
Research and Markets has announced the addition of the "Generic Oncology Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report to their offering. Generic Oncology Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022 provides a comprehensive roadmap for stakeholde
4/24/17 - Growth Opportunities in the Pharmaceutical PPE Market 2017-2021
Dublin- Research and Markets has announced the addition of the "Growth Opportunities in the Pharmaceutical PPE Market, 2016" report to their offering. This market insight covers the growth opportunities for personal protective equipment in the pharmaceutical industry. The study addresses key aspects such as market drivers and restraints, key regula
4/24/17 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 13634) - Workshop
EVENT: Health and Human Services Department; Food and Drug Administration holds a workshop on "Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives," focusing on the current status of regulatory science initiatives for generic drugs and an opportunity for public input on research priorities in this area. LOCATION: FDA White Oak
4/24/17 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 18298) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Oncologic Drugs Advisory Committee to discuss biologics license application 125545, for a proposed biosimilar to Amgen Inc.' s Epogen/Procrit, submitted by Hospira Inc., a Pfizer company, for the treatment of anemia. LOCATION: FDA White Oak Campus, 1090
4/24/17 - Japan's Sawai Pharmaceutical to Acquire the Generics Business of U.S. Upsher-Smith Laboratories
Release date- 21042017- Tokyo and Minnesota] Sawai Pharmaceutical Co. Ltd. (' Sawai'), a leading Japanese generic pharmaceuticals manufacturer, and Upsher-Smith Laboratories, Inc., (' Upsher-Smith'), an established generics manufacturer based in Minnesota, U.S., today announced the signing of an agreement for Sawai to acquire the generic pharmaceut
4/24/17 - More than 50% of life sciences companies will undergo a large-scale transformation this year, yet are unprepared to do so, according to new survey
By a News Reporter-Staff News Editor at Clinical Trials Week TayganPoint Consulting Group, a management consulting firm specializing in business transformation within pharma and the life sciences, has partnered with PharmaVOICE to survey industry executives on how they are responding to current marketplace challenges and pressures- and, if busine
4/24/17 - NetworkNewsBreaks Aegis Capital Reiterates Hold Rating, $2 PT on Intellipharmaceutics International, Inc. (NASDAQ: IPCI)
Aegis Capital has reiterated a Hold rating and price target of $2 on shares of Intellipharmaceutics International. Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
4/24/17 - New Crohn's Disease Study Findings Have Been Reported by Investigators at Department of Medicine [Systematic review with meta-analysis: the efficacy...
New Crohn's Disease Study Findings Have Been Reported by Investigators at Department of Medicine. According to news reporting from Chicago, Illinois, by NewsRx journalists, research stated, "Biosimilars of anti-tumour necrosis factor- agents have now become clinically available for the treatment of inflammatory bowel diseases. The news corresponden
4/24/17 - Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS? (Infliximab-abda) Across All Eligible Indications
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration has approved RENFLEXIS?, a biosimilar referencing Remicade i, across all eligible indications. Samsung Bioepis headquarters in Incheon, Korea. Samsung Bioepis infliximab biosimilar has also been approved for marketing in 28 European Union
4/24/17 - Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
Release date- 21042017- Holzkirchen- Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use has adopted positive opinions, separately recommending the approval of both Sandoz' biosimilar rituximab and biosimilar etanercept in Europe, to treat the same...
4/24/17 - Studies from M. Aapro et al Further Understanding of Neutropenia [Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim...
Studies from M. Aapro et al Further Understanding of Neutropenia[ Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF...]. By a News Reporter-Staff News Editor at Clinical Trials Week Investigators discuss new findings i
4/23/17 - 5 Top NASDAQ Biotech Stocks: Neurocrine Biosciences Gained 32.68 Percent
Late last week Fiercebiotech reported on XBiotech likely getting rejected by the European Medicines Agency. Last week the company revealed its lead candidate is closer to obtaining FDA approval while saying it is tentatively targeting Q4 to launch and NDA. CytRx Corporation gained 40.82 percent last week to finish at $0.61 per share.
4/23/17 - CHMP Recommends Approval Of Sandoz Biosimilar Rituximab And Etanercept In Europe
BASEL- Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use has recommended approval of both Sandoz' biosimilar rituximab and biosimilar etanercept in Europe for the same indications as their respective reference medicines. Subject to EC approval, Sandoz market leadership position extended as the only compa
4/23/17 - Dr. Reddy's Lab launches Progesterone capsules in the U.S. market [India Infoline News Service]
Reddy s Laboratories Ltd., announced on April 21, 2017 that it has launched Progesterone Capsules, 100 mg and 200 mg in U.S. market Dr. Reddy s Laboratories Ltd. announced on April 21, 2017, that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium* capsules in the United States mark
4/22/17 - ICYMI: Sen. Brown 'Leading Charge' to Bring Down Drug Prices
In case you missed it, the Huffington Post today released a story highlighting U.S. Sen. In March, Brown introduced sweeping prescription drug legislation the Huffington Post notes, "combines every policy idea drug lobbyists hate." The legislation follows specific steps Brown outlined to Trump in a December 2016 letter outlining specific steps his.
4/22/17 - Japan`s Sawai Pharma to buy US generics maker [Tehran Times (Iran)]
Sawai Pharmaceutical will buy the generics business of U.S. drugmaker Upsher-Smith Laboratories for $1.05 billion, the Japanese company said Thursday, eager to make up for lost time after its first push into the American market stalled. The company chose Upsher-Smith "because of its nearly 100- year history, as well as its high name recognition in
4/22/17 - Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* [Algeria Press Service]
-Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Holzkirchen, April 21, 2017- Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use has adopted positive opinions, separately recommending t
4/21/17 - $3 million awarded to widow who sued pharmaceutical firm over husband's suicide [Chicago Tribune]
April 21 A Glencoe woman hugged her attorneys after a jury in Chicago awarded her $3 million Thursday in a lawsuit against a pharmaceutical company that she blamed for her husband's suicide. Wendy Dolin's husband, Stewart, stepped in front of a CTA Blue Line train in the Loop on July 15, 2010. Stewart Dolin was a corporate attorney and a partner
4/21/17 - $3M award in suit against drug company over man's suicide
CHICAGO A suburban Chicago woman has been awarded $3 million in a lawsuit against a pharmaceutical company she blamed for her husband's suicide.
4/21/17 - Alvogen to Market Regenerative Fish Skin in Korea, Taiwan and Thailand
Global pharmaceutical company Alvogen will market the Kerecis fish-skin-based diabetic wound treatment products in Asia starting in Korea, Taiwan and Thailand. The Kerecis products will support Alvogen's hospital portfolio. "More than 60 percent of the diabetics in the world live in Asia," said G. Fertram Sigurjonsson, Chairman and CEO of Kerecis.
4/21/17 - Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022
Dublin- Research and Markets has announced the addition of the "Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022" report to their offering. The report entitled Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022 represents an in-depth analysis on th
4/21/17 - Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022 - Research and Markets
Research and Markets has announced the addition of the " Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022" report to their offering. The report entitled Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022 represents an in-depth analysis on the histo
4/21/17 - Celgene Notified of ANDA Filing for POMALYST
By a News Reporter-Staff News Editor at Drug Week Celgene Corporation has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking authorization from the FDA to manufacture and market a generic version of POMALYST 1 mg, 2 mg
4/21/17 - Dr. Reddy's Laboratories Announces the Launch of Progesterone Capsules in the U.S. Market
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd announced today that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium Capsules in the United States market, approved by the U.S. Food and Drug Administration. The Prometrium brand and generic had U.S. sales of
Articles(s): 1 - 25 of 64     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415